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The local route of stem cell administration utilized presently in clinical trials for stress incontinence may not take full advantage
of the capabilities of these cells. The goal of this study was to evaluate if intravenously injected mesenchymal stem cells (MSCs)
home to pelvic organs after simulated childbirth injury in a rat model. Female rats underwent either vaginal distension (VD) or
sham VD. All rats received 2 million GFP-labeled MSCs intravenously 1 hour after injury. Four or 10 days later pelvic organs and
muscles were imaged for visualization of GFP-positive cells. Signiﬁcantly more MSCs home to the urethra, vagina, rectum, and
levator ani muscle 4 days after VD than after sham VD. MSCs were present 10 days after injection but GFP intensity had decreased.
This study provides basic science evidence that intravenous administration of MSCs could provide an eﬀective route for cell-based
therapy to facilitate repair after injury and treat stress incontinence.
1.Introduction
During the second stage of vaginal delivery, pressure of the
fetal head on the pelvic ﬂoor causes direct trauma to the
pelvicmuscles, pelvic ﬂoor organsincluding theurethra, and
the nerves that innervate them [1]. These injuries can lead
to development of pelvic ﬂoor disorders (PFDs), including
pelvic organ prolapse, stress urinary incontinence (SUI) and
fecal incontinence. Available treatment options for SUI and
fecal incontinence include ﬂuid and dietary manipulation,
electricalstimulation,physiotherapy,andpessariesorvaginal
cones [2–4]. Surgery remains the mainstay of treatment
for severe cases of SUI and fecal incontinence as well as
for pelvic organ prolapse. The lifetime risk of undergoing
surgery for PFD has been estimated as 11% [5]. Although
several therapeutic options exist, no current therapy is able
to fully correct the underlying pathophysiology.
Stem cells have been investigated in both animal and
clinical studies as a potential treatment for SUI and have
been demonstrated to improve both function and anatomy
[6–11]. Most of these studies utilized autologous muscle-
derived progenitor cells injected into the urethra to treat
SUIandhavedemonstratedtheirpotentialforclinicalutility;
however,long-termoutcomesarenotyetavailable[12].After
vaginal delivery, the pelvic organs, their innervating nerves,
and connective tissue in the region are injured, which later2 Obstetrics and Gynecology International
c a nl e a dt oP F D .T h e s ed i ﬀuse injuries in multiple organs
may not be successfully treated with local administration of
stem cells to the urethra.
Hematopoetic and mesenchymal stem cells (MSCs)
migrate or home to sites of injury following gradients of
chemokines, such as stromal derived factor 1 (SDF1) and
(C-C motif) ligand 7 (CCL7), previously called MCP-3 [13].
Once localized to tissues, they can diﬀerentiate into diﬀerent
tissue types and produce paracrine and growth factors [14].
Animal models in several ﬁelds have been utilized to demon-
strate MSC homing and resultant facilitation of functional
improvement with a variety of injury models, including car-
diac injury [15, 16], renal failure [17], and skin wounds [18],
demonstrating the clinical potential of this cell population.
Simulation of childbirth injury in female rats by distend-
ing the vagina has become a standard method of modeling
the maternal injuries of childbirth and results in symptoms
ofSUI [19–22].Asimulatedchildbirthinjuryisusedbecause
in all animals, including nonhuman primates, the baby’s
headtobirthcanalratioismuchsmallerthanitisinhumans,
implying that vaginal birth is most traumatic humans [23].
We have previously demonstrated that CCL7 and one of
its receptors CCR1 are upregulated in the urethra after
simulated childbirth injury, indicating a potential for MSC
homing to pelvic organs [24]. The goal of the current study
was to determine to which organs MSCs injected intrave-
nously will home after simulated childbirth injury in female
rats. Although functional studies are left to a follow-up
study, these organs are presumed to be the same ones in
which the cells would have the greatest therapeutic potential.
Once demonstrated in a basic science preclinical model,
intravenously delivered MSCs may serve as an eﬀective route
to deliver stem cells to facilitate repair after childbirth injury
and treat PFD.
2. Methods
2.1. Stem Cell Harvest and Culture. Bone marrow from a
donorfemaleSprague-Dawleyratwasusedtocreatecultured
MSC adapting the methods of Lennon & Caplan [25].
In brief, the rat was euthanized and the femur and tibia
were harvested. The bones were cleaned and both ends
were removed for aspiration of marrow by ﬂushing with
Dulbeco’s Modiﬁed Eagle Medium-Low Glucose solution
supplemented with 12% Fetal Bovine Serum and 1% Anti-
Anti (Invitrogen, Carlsbad, CA) containing penicillin, strep-
tomycin, and amphotericin. The cells were centrifuged and
washed then plated (passage 0). Every other day the media
was changed and, after reaching conﬂuency (80–100%),
the cells were passaged using Trypsin-EDTA. At passage 3
cells were incubated with Intracellular adhesion molecule
I (ICAM-1) antibody (10µL/1 × 106 cells) for 30min at
room temperature in the dark to select for MSC. Cells were
sorted via ﬂow cytometry, and ICAM+ cells were collected
under sterile conditions. These MSC were transfected with
pCCLsin.ppt.hPGK.GFP.pre (a generous gift from the Cossu
Lab) which uses a human PGK promoter to constitutively
express green ﬂuorescent protein (GFP). After reaching
conﬂuency, cells were resorted under sterile conditions and
GFP-positive (GFP+) cells were collected. Cells were grown
to passages 15-16 before being injected in rats.
2.2. Vaginal Distention (VD). All experimental procedures
were approved by the Institutional Animal Care and Use
Committee of the Cleveland Clinic. Age-matched virgin
female Sprague-Dawley rats (240265g) underwent either a
simulated childbirth injury by vaginal distension (VD; n =
11) or sham VD (n = 1 1 ) .V Dw a sp e r f o r m e da sw eh a v e
done previously [24]. In brief, each rat was anesthetized, a
modiﬁed 10Fr Foley catheter was inserted into the vagina
and the balloon was inﬂated to 3mL for 4 hours. Sham VD
consisted of catheter insertion for 4 hours without balloon
inﬂation. 1 hour after injury, the animals were anesthetized
with isoﬂurane and sodium nitroprusside was administered
via the lateral tail vein at 1mg/kg for 1 minute. Immediately
following,2millionGFP-labeledMSCsin1mLofsalinewere
injected via the lateral tail vein.
2.3. Fluorescent Imaging. Four or 10 days after VD or
sham VD, a sham VD and VD pair were anesthetized and
imagedsimultaneouslyinvivo forvisualizationof GFP+ cells
using a supercooled charge-coupled camera in a light tight
box. Immediately afterward the urinary bladder, urethra,
vagina, rectum, and levator ani muscles were harvested from
each animal and imaged similarly ex vivo.T o t a lﬂ u o r e s c e n t
ﬂux (photons/second/cm2/steradian) in a region of interest
selected around each organ from ex vivo imaging was calcu-
lated.ValuesfromVDanimalswerenormalizedtothatofthe
paired sham VD animal which was imaged simultaneously.
2.4. Flow Cytometry. To validate quantitative values of ﬂux
from ex vivo imaging, we processed the tissues and analyzed
individual cells by ﬂow cytometry. After organs were imaged
ex vivo they were minced into 1mm pieces and dissociated
with a collagenase/DNase (2mg/mL collagenase I, 120units/
mL Dnase I; Worthington Biochemical Co., Lakewood, NJ)
mixture for 4 hours until a single cell suspension was
obtained. Control organs were harvested from rats that have
not received MSC and were processed identically to the
experimental groups. Each cell suspension was incubated
with DRAQ5 (BioStatus Limited, London UK), a nuclear
stain and ﬁxed overnight in 1% formalin with FACS buﬀer
(1xPBS, 25mM HEPES, 1% inactivated FBS, .1% sodium
azide, 1mM EDTA). The samples were then permeabilizied
(FACS buﬀer + 0.2% saponin), blocked (Perm buﬀer + 4%
heatinactivatedFBS),andstainedwithrabbitAnt-GFPAlexa
Fluor 488 antibody (Invitrogen, Carlsbad, CA). Cells were
then incubated for 20min in Perm buﬀer centrifuged and
resuspended in FACS buﬀer and ﬁltered through a 30µm
ﬁlter. Labeled cells were maintained on ice prior to ﬂow
cytometric analysis.
The LSRII ﬂow cytometer (BD, Franklin Lakes, NJ) was
calibrated before each experiment using LinearFlow (Invit-
rogen) ﬂuorescent intensity standards to ensure uniform
ﬂuorescent detection throughout the study. Although cells
isolated from diﬀerent organs required FSC/SSC cytometer
adjustments, all samples within an organ group were col-
lected with similar scatter proﬁles.Obstetrics and Gynecology International 3
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Figure 1: Examples of in vivo ﬂuorescence images for GFP+
mesenchymal stem cells 4 and 10 days after vaginal distension (VD)
a n ds h a mV D .T h ec o l o r e ds c a l er e p r e s e n t st o t a lﬂ u o r e s c e n tﬂ u x
(photons/second/cm2/steradian).
For each control organ 10,000 events were collected to
obtain baseline values and 200,000 events were collected
from each sample. Analysis was done using FlowJo 9.1
(Treestar, Ashland, OR). Events were initially gated on
Forward Scatter Width (FSC-W) and Forward Scatter Area
(FSC-A) to obtain a singlet population. Additional gating on
DRAQ5 ﬂuorescent intensity versus Side Scatter Area (SSC-
A) minimized inclusion of noncellular events in the analysis.
Finally, DRAQ5+ events were analyzed for the presence of
GFP+cellsandresultswerecomparedbetweenShamandVD
using uniform gating within each organ group.
2.5.DataAnalysis. Quantitativevaluesarepresentedasmean
± standard error of the mean. Statistical comparisons were
made using a Student’s t-test with P<0.05 indicating a
signiﬁcant diﬀerence between groups. In vivo imaging data
was analyzed qualitatively.
3. Results
In vivo imaging demonstrated evidence of GFP+ MSCs in
the pelvic region both 4 and 10 days after VD (Figure 1).
However, due to the proximity of the pelvic organs, it was
impossible to utilize in vivo imaging to determine which of
the pelvic organs contained more MSCs at these time points.
Four days after VD, relative ﬂux of ﬂuorescence imaged
ex vivo in the urethra (2.9 ± 0.7; P<0.01), vagina (2.0 ±
0.4; P = 0.03), rectum (3.4 ± 1.4; P = 0.02) and levator
ani (1.9 ± 0.4; P = 0.01) was signiﬁcantly greater than after
sham VD (deﬁned as 1; Figures 2 and 3). Ten days after VD,
relative ﬂux of ﬂuorescence was signiﬁcantly greater after
VD (1.6 ± 0.2; P<0.01) than after sham VD (deﬁned as
1) only in the urethra. At this time point, a trend towards
signiﬁcancewaspresentinrelativeﬂuxforthelevatorani(1.9
± 0.6; P = 0.07) and vagina (2.4 ± 0.9; P = 0.07) after VD
compared to sham VD. There was no signiﬁcant diﬀerence
in relative ﬂux in the urinary bladder between VD and sham
VD either 4 or 10 days after injury. Similarly, there was no
signiﬁcant diﬀerence in relative ﬂux in the rectum between
VD and sham VD 10 days after injury (Figures 2 and 3).
There was a signiﬁcant decrease in total ﬂux from 4 to
10 days after sham VD for the vagina (P = 0.02), levator ani
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Figure 2: Examples of ex vivo ﬂuorescence images for GFP+
mesenchymal stem cells in the urethra, vagina, bladder, rectum,
and levator ani 4 and 10 days after vaginal distension (VD)
and sham VD. Each column contains organs taken from a
single animal. The colored scale represents total ﬂuorescent ﬂux
(photons/second/cm2/steradian).
(P = 0.02), and rectum (P<0.0 1 ) ,a sw e l la sat r e n dt o w a r d s
signiﬁcant decrease after sham VD from 4 to 10 days in the
urethra (P = 0.05), and bladder (P = 0.07; Figure 4). There
was a signiﬁcant decrease in total ﬂux from 4 to 10 days after
VD in the urethra (P = 0.03), rectum (P<0.01), and levator
ani (P<0.01). There was a trend towards a signiﬁcance
decrease in total ﬂux from 4 to 10 days after VD in the vagina
(P = 0.07) and bladder (P = 0.09).
Flow cytometry results for all organs at both timepoints
were highly variable in scatter properties, background auto-
ﬂuorescence, and in DRAQ5 staining; therefore no statisti-
cally signiﬁcant diﬀerences between groups could be deter-
mined.
4. Discussion
Vaginal childbirth can cause injury to pelvic organs, pelvic
ﬂoor muscles, and the pudendal nerve, among other struc-
tures, which can lead to PFD [1]. Two-thirds of women who
have delivered vaginally experience at least one type of PFD
[26].Symptomsofthesedisorderscancausesocialandsexual
isolation, restriction of employment, and reduced quality of
life [27]. Symptoms often do not develop until years after
the original injury [28] suggesting that although some repair
may occur after childbirth, it is imperfect and insuﬃcient in
the long term.
Cell-based therapy is gaining attention as a potential
treatment, particularly for SUI [29, 30]. Preclinical investi-
gations in animal models have utilized stem cells obtained
from adipose tissue [6, 31], bone marrow [32], or muscle
[33, 34]. Initial clinical studies have reported improvement
inSUIafteranautologousinjectionofstemcellsdirectlyinto
the urethra [8, 12]. Some of the preclinical studies utilize
simulated childbirth injury models involving pregnant rats
[6, 35, 36] and others do not [21, 24, 37–39]. Although4 Obstetrics and Gynecology International
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Figure 3: Relative ﬂuorescent ﬂux measured ex vivo (a) four days and (b) ten days after vaginal distension (VD) normalized to total
ﬂuorescent ﬂux in paired animals that underwent sham VD simultaneously. Values are displayed as mean ± standard error of 5-6
animals/group as a percent of the sham VD values. ∗ denotes a statistically signiﬁcant diﬀerence compared to sham VD (P<0.05).
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Figure 4: Total ﬂuorescent ﬂux 4 and 10 days after (a) sham vaginal distension and (b) vaginal distension (VD). Values are displayed as
mean ± standard error of 5-6 animals/group. ∗ denotes a statistically signiﬁcant diﬀerence compared to the same organs 10 days after sham
VD or VD (P<0.05).
diﬀerent investigators utilize diﬀerent outcome measures,
making comparisons diﬃcult; the overall results are quite
similar and indicate that the urethra and vagina sustain
signiﬁcant injury to muscles, connective tissue, innervation,
and vascularization [19].
Intravenous administration is less invasive than peri-
urethral or intraurethral injections and has been shown to be
aneﬀectiveroutetodeliverstemcellsandfacilitatefunctional
improvement in cardiac ischemia [40] and ischemic stroke
[41]models.Additionally,intravenousadministrationallows
the stem cells to home to and target the multiple organs
that are damaged during childbirth injury compared with a
direct injection that would potentially treat the target organ
only. Lin et al. demonstrated that intravenously delivered
adipose-derived stem cells can migrate to the urethra after
simulated childbirth injury and improve urethral function
[6]. However, an investigation of the migration, or homing,
of the cells to diﬀerent pelvic organs was not made.
While there are several diﬀerent methods of labeling
and tracking infused cells, GFP is commonly used, in part
becausediﬀerentiationofMSCdoesnotalterGFPexpression
[42]. In vivo imaging in our study showed a strong GFP
signal in the pelvic region after VD, indicating the presence
of GFP+ MSC in the structures of the pelvic region. In vivoObstetrics and Gynecology International 5
ﬂuorescence was not as prominent in the pelvic region after
sham VD, likely because of reduced homing after sham VD
compared to VD, leading to lower ﬂuorescence in the pelvic
region, coupled with the depth of pelvic organs underneath
the pelvic bone. Nonetheless, our results indicate that GFP-
labeled MSCs are potentially useful for the monitoring
of cell migration, homing, engraftment, and survival of
transplanted MSCs in pelvic organs.
Ex vivo imaging demonstrated that allogenic MSCs
migrated to the urethra, vagina, levator ani muscles, and
rectum to a greater extent after VD than after sham VD,
conﬁrming that tissue injury plays an important role in
homing of MSCs to the pelvic organs since these tissues
have previously been shown to incur greater damage after
VD than sham VD [37, 43]. The vagina and urethra have
been studied to the greatest extent after VD since they
demonstrate the greatest damage [6, 19, 37, 43]. Our data
suggests that damage to the levator ani and rectum ought to
be investigated as well.
After injury, peripheral tissues release chemokines that
cause mobilization and attract MSCs to engraft in the
tissue via a cytokine gradient [14]. We have previously
reported that CCL7, a known stem cell homing cytokine,
is upregulated in rat urethra and vagina but not in the
rectum or bladder immediately following VD [38]. We also
found a positive relationship between duration of VD and
the subsequent expression of CCL7 and its receptor, CCR1,
in the urethra [24]. In contrast to this previous work, the
current study demonstrated that MSC also home to the
rectum after VD, suggesting that there are other factors as yet
undiscovered that may play a signiﬁcant role in the homing
of MSC to pelvic organs after VD.
Hypoxia of tissues has been previously shown to upreg-
ulate cytokines that attract MSC and play a signiﬁcant
role in MSC homing [44]. Although our previous work
demonstrated signiﬁcant hypoxia in the bladder after VD
[37], the current study did not show any increase in homing
of MSC to the bladder after VD compared to sham VD.
Interestingly, the previous work also demonstrated hypoxia
of the bladder after sham VD [44]. It is possible that the
homingofMSCtothebladderaftershamVDwassuﬃciently
high so no diﬀerence was demonstratable compared to VD.
The signiﬁcant reduction in total ﬂuorescent ﬂux by 10
daysafterVDinallorgansis indicative ofasigniﬁcantreduc-
tion in MSC, which may have been due to cell death. Poor
viability of MSC after cell transplantation in myocardium
has previously been reported [45, 46]. Anoikis, a loss of cell
to matrix adhesion resulting in a reduction of repression
of apoptotic signal [47], may have been occurring in these
cells after transplantation. Future research will be designed
to investigate the fate of cells that home to pelvic organs after
VD. Despite their low survival rate, we have demonstrated in
a parallel study, that MSCs infused intravenously facilitate a
rapid improvement of urethral function after VD, likely via a
paracrine mechanism of action [48].
We performed ﬂow cytometry to validate the ex vivo
imaging results and quantify the number of GFP+ MSC
engrafted in each organ. However, despite careful gating
and backgating of subpopulations on multiple parameters
to ensure authenticity, the results showed high variability
in scatter and ﬂuorescent properties among controls and
sampleswithineachorgangroup,indicatingthatourcurrent
technique was not suﬃcient at preserving the cells. Flow
cytometry has been previously utilized to determine that 1–
5% of the cells in the heart are MSCs after an intravenous
MSC infusion [15], which has been conﬁrmed by other
methods as well [40, 49]. Although it is likely that fewer than
2% of total cells were MSCs in the urethra after VD in our
study, due to the smaller size and lower vascularization of
this organ, it is possible that with technical improvements
we could detect these cells. Future work will be focused on
improving these techniques.
One potential limitation of our animal model is that it
relieson stemcellhomingafteranacutesimulatedchildbirth
injury although SUI and other PFD manifest and are treated
years after the original injury. The cell-based therapies we
investigated could be administered soon after delivery in
women who are at highest risk for development of PFD
such as women with genetic predispositions [50–52]o r
those with postpartum SUI [30, 53, 54] .T h el a t t e ri sm o s t
intriguing because the cell-based therapy may both treat
their postpartum SUI and prevent later recurrence of SUI.
In addition, it may be possible to induce homing a long
time after injury or increase homing after an acute injury via
geneticmodiﬁcationofstemcellstoexpressagreaternumber
of homing ligands [55]. Furthermore it may be possible to
administer electrical stimulation to the paravaginal region,
which has been shown in vitro to induce cell migration
of neural stem cells [56], human-induced pluripotent stem
cells [57], and adipose-derived MSCs [58]. Further research
utilizing preclinical animal models will be needed to initiate
clinical trials of these therapies.
Although we investigated stem cell homing after simu-
lated childbirth injury, it has been shown that potentially
stem cells do not necessarily need to home to injured tissue
to improve function [59]. Therefore, it is possible that MSCs
could accelerate recovery at sites distant from those where
cells migrate or home, suggesting a systemic paracrine eﬀect
of the cells. Further research is needed to determine the
mechanism of homing and accelerated recovery with cell-
based therapies.
5. Conclusion
We conclude from this study that MSC preferentially home
to the urethra, vagina, levator ani, and rectum after simu-
lated childbirth injury, providing evidence that intravenous
administration of MSCs could be a potentially eﬀective
method of delivering cell-based therapies after vaginal
childbirth injury.
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